Condensed Consolidated Statement of Changes in Shareholders' Deficit - USD ($)
|
Total |
Common Stock [Member] |
Additional Paid-in Capital [Member] |
Accumulated Deficit [Member] |
| Balance at Dec. 31, 2013 |
$ (5,053,185)
|
$ 2,174
|
$ 3,974,007
|
$ (9,029,366)
|
| Balance (in shares) at Dec. 31, 2013 |
|
21,740,006
|
|
|
| Conversion of Series A and Series B preferred stock to common stock |
1,419,410
|
$ 164
|
1,419,246
|
0
|
| Conversion of Series A and Series B preferred stock to common stock (in shares) |
|
1,637,000
|
|
|
| Stock based compensation |
1,203,663
|
$ 0
|
1,203,663
|
0
|
| Issuance of common stock for consulting services |
25,000
|
$ 4
|
24,996
|
|
| Issuance of common stock for consulting services (in shares) |
|
43,860
|
|
|
| Exercise of common stock warrants |
6,132
|
$ 61
|
6,071
|
|
| Exercise of common stock warrants (in shares) |
|
613,228
|
|
|
| Net loss |
(9,253,323)
|
$ 0
|
0
|
(9,253,323)
|
| Balance at Dec. 31, 2014 |
(11,652,303)
|
$ 2,403
|
6,627,983
|
(18,282,689)
|
| Balance (in shares) at Dec. 31, 2014 |
|
24,034,094
|
|
|
| Conversion of Series A and Series B preferred stock to common stock |
18,524,163
|
$ 2,136
|
18,522,027
|
0
|
| Conversion of Series A and Series B preferred stock to common stock (in shares) |
|
21,363,000
|
|
|
| Issuance of additional common stock upon Series A anti-dilution (in shares) |
|
3,208,077
|
|
|
| Issuance of common stock warrants |
1,817,672
|
|
1,817,672
|
|
| Stock based compensation |
722,934
|
$ 0
|
722,934
|
0
|
| Exercise of common stock warrants |
5,651
|
57
|
5,594
|
|
| Issuance of additional common stock upon Series A anti-dilution |
0
|
$ 321
|
(321)
|
|
| Exercise of common stock warrants (in shares) |
|
565,061
|
|
|
| Net loss |
(9,441,535)
|
$ 0
|
0
|
(9,441,535)
|
| Balance at Dec. 31, 2015 |
(23,419)
|
$ 4,917
|
27,695,888
|
(27,724,224)
|
| Balance (in shares) at Dec. 31, 2015 |
|
49,170,232
|
|
|
| Conversion of Series A and Series B preferred stock to common stock |
193,650
|
$ 43
|
193,607
|
0
|
| Conversion of Series A and Series B preferred stock to common stock (in shares) |
|
430,000
|
|
|
| Stock based compensation |
414,687
|
$ 0
|
414,687
|
0
|
| Exercise of common stock warrants |
274
|
$ 2
|
271
|
0
|
| Exercise of common stock warrants (in shares) |
|
27,364
|
|
|
| Net loss |
(4,320,991)
|
$ 0
|
0
|
(4,320,991)
|
| Balance at Jun. 30, 2016 |
$ (3,735,800)
|
$ 4,962
|
$ 28,304,453
|
$ (32,045,215)
|
| Balance (in shares) at Jun. 30, 2016 |
|
49,627,596
|
|
|